Sarepta shares rise as new DMD drug succeeds early stage trial

(Reuters) - Sarepta Therapeutics Inc's shares jumped about 15 percent on Wednesday after the company's drug to treat patients with a form of a fatal muscle-wasting disease met the main goal of an early-stage trial.